ctrl K

Watchlist Price Alert

Virax Biolabs Group Limit... (VRAX)

NASDAQ: VRAX · Real-Time Price · USD

1.07

-0.01 (-1.38%)

At close: May 15, 2025, 2:08 PM

Virax Biolabs Income Statement

Financials in USD. Fiscal year is April - March.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Revenue	156.42K	8.56K	n/a	123.82K	99.88K
Cost of Revenue	105.83K	9.93K	n/a	133.25K	54.13K
Gross Profit	50.59K	-1.36K	n/a	-9.43K	45.75K
Operating Income	-6.5M	-5.73M	-1.73M	-644.54K	-651.24K
Interest Income	n/a	15.47K	15.44K	28.64K	90.69K
Pretax Income	-6.74M	-5.46M	-1.75M	-672.91K	-739.46K
Net Income	-6.73M	-5.46M	-1.71M	-650.98K	-801.13K
Selling & General & Admin	4.59M	5.33M	1.3M	514.88K	609.99K
Research & Development	1.56M	397.11K	433.74K	120.22K	87K
Other Expenses	390.36K	290.47K	n/a	266.00	2.47K
Operating Expenses	6.55M	5.73M	1.73M	635.1K	696.99K
Interest Expense	26.88K	15.47K	15.44K	28.64K	90.69K
Selling & Marketing Expenses	n/a	26.62K	13.82K	57.2K	7.69K
Cost & Expenses	6.65M	5.74M	1.73M	768.36K	751.12K
Income Tax Expense	n/a	-271	-1.77M	-666.47K	61.67K
Shares Outstanding (Basic)	2.01M	1.06M	1.14M	1.14M	1.14M
Shares Outstanding (Diluted)	2.01M	1.06M	1.14M	1.14M	1.14M
EPS (Basic)	-3.36	-5.13	-1.5	-0.57	-0.7
EPS (Diluted)	-3.36	-5.13	-1.5	-0.57	-0.7
EBITDA	-6.61M	-5.44M	-750	n/a	-648.77K
EBIT	-6.71M	-5.44M	-1.73M	-644.27K	-648.77K
Depreciation & Amortization	103.1K	n/a	1.73M	644.54K	651.24K